Contrasting iRadimed (NASDAQ:IRMD) and Jushi (OTCMKTS:JUSHF)

iRadimed (NASDAQ:IRMDGet Free Report) and Jushi (OTCMKTS:JUSHFGet Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation.

Institutional and Insider Ownership

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 21.7% of Jushi shares are owned by institutional investors. 34.6% of iRadimed shares are owned by insiders. Comparatively, 23.1% of Jushi shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current recommendations and price targets for iRadimed and Jushi, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRadimed 0 1 3 1 3.00
Jushi 0 0 1 0 3.00

iRadimed currently has a consensus target price of $120.00, suggesting a potential upside of 45.95%. Given iRadimed’s higher possible upside, research analysts clearly believe iRadimed is more favorable than Jushi.

Risk and Volatility

iRadimed has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, Jushi has a beta of -0.63, meaning that its share price is 163% less volatile than the S&P 500.

Earnings & Valuation

This table compares iRadimed and Jushi”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iRadimed $86.34 million 12.18 $22.48 million $1.79 45.93
Jushi $262.91 million 0.32 -$68.59 million ($0.34) -1.22

iRadimed has higher earnings, but lower revenue than Jushi. Jushi is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares iRadimed and Jushi’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
iRadimed 26.70% 23.45% 20.36%
Jushi -24.44% N/A -15.46%

Summary

iRadimed beats Jushi on 13 of the 14 factors compared between the two stocks.

About iRadimed

(Get Free Report)

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.

About Jushi

(Get Free Report)

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

Receive News & Ratings for iRadimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRadimed and related companies with MarketBeat.com's FREE daily email newsletter.